Pyxis Oncology Announces FDA Clearance of Two IND Applications

 FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate

Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity in patients with select solid tumors

Dual IND clearances represent achievement of significant 2022 milestones and executional pipeline advancement

Cash runway extended into first half 2025

https://finance.yahoo.com/news/pyxis-oncology-announces-fda-clearance-114500640.html